BSc/LLB(Hons) graduate from University of Technology Sydney.
J Law Med. 2023 Dec;30(4):884-898.
The mapping and sequencing of the human genome at the turn of the new millennium marks a pivotal reassessment of genomic science in its potential to replace traditional "one-size-fits-all" medicine with a personalised approach. The use of racial proxies in the development of pharmacogenomic products risks conflating genetics with race under the guise of alleviating health disparities. This article argues that the current genomic approaches to realising personalised medicine do not deliver on the promise for optimised health for all and may result in irreversible harm, including psychological, social and medical harm, to racial minority groups. In light of recent epigenetic findings, the article provides a reconceptualisation of the genome and race, which is necessary to understand enduring racial disparities and the cumulative effects of racial discrimination. It then addresses the need for regulatory oversight of the approval of race-based pharmacogenomic products.
在新千年之交,人类基因组的绘制和测序标志着基因组科学的一个关键的重新评估,其有可能用个性化的方法取代传统的“一刀切”的医学。在开发药物基因组学产品时使用种族代理有将遗传学与种族混为一谈的风险,其借口是减轻健康差距。本文认为,目前实现个性化医学的基因组方法并没有兑现为所有人实现最佳健康的承诺,反而可能对少数族裔群体造成不可逆转的伤害,包括心理、社会和医疗伤害。鉴于最近的表观遗传学发现,本文对基因组和种族进行了重新概念化,这对于理解持久的种族差异和种族歧视的累积效应是必要的。然后,它还讨论了需要对基于种族的药物基因组学产品的批准进行监管监督。